On the other hand, we also observed patients as well as cell lines that exhibited decreased CD73 expression following RAS‐MAPK‐targeted treatment, supporting recent studies showing that melanoma patients experienced decreased CD73 expression during BRAF treatment [18]. The gene discussed is NT5E; the disease is melanoma.